Veracyte (VCYT) Competitors

$38.90 +0.65 (+1.70%)

Closing price 04:00 PM Eastern

Extended Trading

$38.87 -0.03 (-0.08%)

As of 04:50 PM Eastern

VCYT vs. TWST, BTSG, HIMS, CELC, and CAI

Should you buy Veracyte stock or one of its competitors? MarketBeat compares Veracyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Veracyte include Twist Bioscience (TWST), BrightSpring Health Services (BTSG), Hims & Hers Health (HIMS), Celcuity (CELC), and Caris Life Sciences (CAI).

How does Veracyte compare to Twist Bioscience?

Twist Bioscience (NASDAQ:TWST) and Veracyte (NASDAQ:VCYT) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Veracyte has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$409.48M	8.05	-$77.67M	-$1.33	N/A
Veracyte	$541.74M	5.72	$66.35M	$1.09	35.65

Twist Bioscience has a beta of 2.22, suggesting that its stock price is 122% more volatile than the broader market. Comparatively, Veracyte has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market.

Veracyte has a net margin of 16.25% compared to Twist Bioscience's net margin of -19.85%. Veracyte's return on equity of 9.07% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
Veracyte	16.25%	9.07%	8.38%

Twist Bioscience presently has a consensus price target of $56.57, suggesting a potential upside of 6.90%. Veracyte has a consensus price target of $44.83, suggesting a potential upside of 15.37%. Given Veracyte's higher possible upside, analysts plainly believe Veracyte is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Veracyte	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, Twist Bioscience had 1 more articles in the media than Veracyte. MarketBeat recorded 12 mentions for Twist Bioscience and 11 mentions for Veracyte. Twist Bioscience's average media sentiment score of 1.07 beat Veracyte's score of 0.68 indicating that Twist Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veracyte	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Veracyte beats Twist Bioscience on 8 of the 14 factors compared between the two stocks.

How does Veracyte compare to BrightSpring Health Services?

BrightSpring Health Services (NASDAQ:BTSG) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

Veracyte has a net margin of 16.25% compared to BrightSpring Health Services' net margin of 2.27%. BrightSpring Health Services' return on equity of 14.63% beat Veracyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BrightSpring Health Services	2.27%	14.63%	4.41%
Veracyte	16.25%	9.07%	8.38%

BrightSpring Health Services has higher revenue and earnings than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than BrightSpring Health Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BrightSpring Health Services	$12.91B	0.88	$190.67M	$1.41	41.42
Veracyte	$541.74M	5.72	$66.35M	$1.09	35.65

In the previous week, Veracyte had 4 more articles in the media than BrightSpring Health Services. MarketBeat recorded 11 mentions for Veracyte and 7 mentions for BrightSpring Health Services. BrightSpring Health Services' average media sentiment score of 0.95 beat Veracyte's score of 0.68 indicating that BrightSpring Health Services is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BrightSpring Health Services	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veracyte	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BrightSpring Health Services presently has a consensus price target of $56.29, suggesting a potential downside of 3.63%. Veracyte has a consensus price target of $44.83, suggesting a potential upside of 15.37%. Given Veracyte's higher probable upside, analysts clearly believe Veracyte is more favorable than BrightSpring Health Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BrightSpring Health Services	0 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	3.12
Veracyte	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

BrightSpring Health Services has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market. Comparatively, Veracyte has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market.

Summary

BrightSpring Health Services beats Veracyte on 9 of the 15 factors compared between the two stocks.

How does Veracyte compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and Veracyte (NASDAQ:VCYT) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Veracyte has a net margin of 16.25% compared to Hims & Hers Health's net margin of -0.56%. Veracyte's return on equity of 9.07% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-0.56%	6.10%	1.52%
Veracyte	16.25%	9.07%	8.38%

Hims & Hers Health has higher revenue and earnings than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.35B	2.35	$128.37M	$0.51	47.52
Veracyte	$541.74M	5.72	$66.35M	$1.09	35.65

63.5% of Hims & Hers Health shares are owned by institutional investors. 11.8% of Hims & Hers Health shares are owned by company insiders. Comparatively, 1.4% of Veracyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Hims & Hers Health had 62 more articles in the media than Veracyte. MarketBeat recorded 73 mentions for Hims & Hers Health and 11 mentions for Veracyte. Veracyte's average media sentiment score of 0.68 beat Hims & Hers Health's score of 0.02 indicating that Veracyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	16 Very Positive mention(s)	11 Positive mention(s)	9 Neutral mention(s)	24 Negative mention(s)	5 Very Negative mention(s)	Neutral
Veracyte	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hims & Hers Health presently has a consensus price target of $29.50, suggesting a potential upside of 21.73%. Veracyte has a consensus price target of $44.83, suggesting a potential upside of 15.37%. Given Hims & Hers Health's higher possible upside, analysts plainly believe Hims & Hers Health is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	2 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.12
Veracyte	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Hims & Hers Health has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market. Comparatively, Veracyte has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market.

Summary

Veracyte beats Hims & Hers Health on 8 of the 15 factors compared between the two stocks.

How does Veracyte compare to Celcuity?

Celcuity (NASDAQ:CELC) and Veracyte (NASDAQ:VCYT) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Celcuity has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, Veracyte has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market.

63.3% of Celcuity shares are owned by institutional investors. 13.3% of Celcuity shares are owned by insiders. Comparatively, 1.4% of Veracyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Veracyte had 3 more articles in the media than Celcuity. MarketBeat recorded 11 mentions for Veracyte and 8 mentions for Celcuity. Celcuity's average media sentiment score of 1.28 beat Veracyte's score of 0.68 indicating that Celcuity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Veracyte	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Celcuity presently has a consensus target price of $134.50, suggesting a potential downside of 0.25%. Veracyte has a consensus target price of $44.83, suggesting a potential upside of 15.37%. Given Veracyte's higher possible upside, analysts plainly believe Veracyte is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Veracyte	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Veracyte has a net margin of 16.25% compared to Celcuity's net margin of 0.00%. Veracyte's return on equity of 9.07% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-203.17%	-52.68%
Veracyte	16.25%	9.07%	8.38%

Veracyte has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$3.79	N/A
Veracyte	$541.74M	5.72	$66.35M	$1.09	35.65

Summary

Veracyte beats Celcuity on 10 of the 15 factors compared between the two stocks.

How does Veracyte compare to Caris Life Sciences?

Veracyte (NASDAQ:VCYT) and Caris Life Sciences (NASDAQ:CAI) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

In the previous week, Caris Life Sciences had 15 more articles in the media than Veracyte. MarketBeat recorded 26 mentions for Caris Life Sciences and 11 mentions for Veracyte. Veracyte's average media sentiment score of 0.68 beat Caris Life Sciences' score of 0.16 indicating that Veracyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caris Life Sciences	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral

Veracyte presently has a consensus price target of $44.83, suggesting a potential upside of 15.37%. Caris Life Sciences has a consensus price target of $27.56, suggesting a potential upside of 81.24%. Given Caris Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Caris Life Sciences is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Caris Life Sciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Veracyte has a net margin of 16.25% compared to Caris Life Sciences' net margin of 3.75%. Caris Life Sciences' return on equity of 98.28% beat Veracyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	16.25%	9.07%	8.38%
Caris Life Sciences	3.75%	98.28%	48.87%

Veracyte has higher earnings, but lower revenue than Caris Life Sciences. Caris Life Sciences is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$541.74M	5.72	$66.35M	$1.09	35.65
Caris Life Sciences	$812.03M	5.29	-$68.09M	-$7.61	N/A

Summary

Caris Life Sciences beats Veracyte on 7 of the 13 factors compared between the two stocks.

Get Veracyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCYT vs. The Competition

Export

Metric	Veracyte	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.10B	$6.69B	$6.29B	$12.46B
Dividend Yield	N/A	1.72%	2.79%	5.30%
P/E Ratio	35.65	49.59	20.87	25.61
Price / Sales	5.72	43.34	521.62	63.45
Price / Cash	26.56	24.21	42.94	55.34
Price / Book	2.31	6.50	9.86	6.71
Net Income	$66.35M	$158.34M	$3.55B	$333.77M
7 Day Performance	-4.66%	-2.32%	-0.26%	0.40%
1 Month Performance	13.30%	-1.73%	1.39%	4.03%
1 Year Performance	36.40%	-1.67%	41.07%	36.33%

Veracyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCYT Veracyte	2.9398 of 5 stars	$38.90 +1.7%	$44.83 +15.3%	+30.5%	$3.10B	$541.74M	35.69	790
TWST Twist Bioscience	1.9205 of 5 stars	$56.19 -7.0%	$48.38 -13.9%	+68.4%	$3.70B	$376.57M	N/A	990
BTSG BrightSpring Health Services	3.5468 of 5 stars	$53.54 +1.8%	$54.64 +2.1%	+143.1%	$10.16B	$12.91B	37.97	23,500
HIMS Hims & Hers Health	4.2021 of 5 stars	$27.25 -0.6%	$32.53 +19.4%	-62.3%	$6.25B	$2.35B	53.43	2,442	Trending News Earnings Report Analyst Forecast Options Volume
CELC Celcuity	1.8383 of 5 stars	$144.98 +15.4%	$134.50 -7.2%	+1,050.4%	$6.07B	N/A	N/A	40	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCYT) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veracyte (VCYT) Competitors

VCYT vs. TWST, BTSG, HIMS, CELC, and CAI

How does Veracyte compare to Twist Bioscience?

Summary

How does Veracyte compare to BrightSpring Health Services?

Summary

How does Veracyte compare to Hims & Hers Health?

Summary

How does Veracyte compare to Celcuity?

Summary

How does Veracyte compare to Caris Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT vs. The Competition

Veracyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veracyte (VCYT) Competitors

VCYT vs. TWST, BTSG, HIMS, CELC, and CAI

How does Veracyte compare to Twist Bioscience?

Which has higher valuation and earnings, TWST or VCYT?

Which has more risk and volatility, TWST or VCYT?

Is TWST or VCYT more profitable?

Do analysts prefer TWST or VCYT?

Does the media favor TWST or VCYT?

Summary

How does Veracyte compare to BrightSpring Health Services?

Is BTSG or VCYT more profitable?

Which has stronger valuation and earnings, BTSG or VCYT?

Does the media prefer BTSG or VCYT?

Do analysts recommend BTSG or VCYT?

Which has more volatility and risk, BTSG or VCYT?

Summary

How does Veracyte compare to Hims & Hers Health?

Is HIMS or VCYT more profitable?

Which has higher valuation & earnings, HIMS or VCYT?

Do institutionals and insiders have more ownership in HIMS or VCYT?

Does the media refer more to HIMS or VCYT?

Do analysts prefer HIMS or VCYT?

Which has more risk & volatility, HIMS or VCYT?

Summary

How does Veracyte compare to Celcuity?

Which has more volatility and risk, CELC or VCYT?

Do insiders & institutionals hold more shares of CELC or VCYT?

Does the media prefer CELC or VCYT?

Do analysts prefer CELC or VCYT?

Is CELC or VCYT more profitable?

Which has stronger valuation and earnings, CELC or VCYT?

Summary

How does Veracyte compare to Caris Life Sciences?

Does the media refer more to VCYT or CAI?

Do analysts prefer VCYT or CAI?

Is VCYT or CAI more profitable?

Which has preferable valuation & earnings, VCYT or CAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT vs. The Competition

Veracyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools